Effects of sugammadex on activated partial thromboplastin time and prothrombin time in healthy subjects

International Journal of Clinical Pharmacology and Therapeutics

Volumn 52, Issue 3, 2014, Pages 227-236

  De Kam, Pieter Jan ^a   Grobara, Peter ^b   Prohn, Marita ^b   Höppener, Floris ^c   Kluft, Cornelis ^d,e   Burggraaf, Jacobus ^d   Langdon, Ronald B ^b   Peeters, Pierre ^b,d  

^a MERCK RESEARCH LABORATORIES   (United States)

^b MSD Oss BV   (Netherlands)

^c Kendle International BV   (Netherlands)

^d CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^e Good Biomarker Sciences   (Netherlands)

Author keywords

Hemostasis parameters; International normalized ratio; Neuromuscular blockade; Pharmacodynamics; Pharmacokinetics

Indexed keywords

CITRIC ACID; PLACEBO; SUGAMMADEX;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD CLOTTING TIME; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; FEMALE; HUMAN; HUMAN EXPERIMENT; HYPERSENSITIVITY; IN VITRO STUDY; INTERNATIONAL NORMALIZED RATIO; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OUTCOME ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; PHARMACODYNAMICS; POLLAKISURIA; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT;

ADULT; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GAMMA-CYCLODEXTRINS; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; YOUNG ADULT;

EID: 84895476030     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201976     Document Type: Article

References (28)

1. Berg H, Roed J, Viby-Mogensen J, Mortensen CR, Engbaek J, Skovgaard LT, Krintel JJ. Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective, randomised, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium. Acta Anaesthesiol Scand. 1997; 41: 1095-1103. CrossRef PubMed
2. Baillard C, Gehan G, Reboul-Marty J, Larmignat P, Samama CM, Cupa M. Residual curarization in the recovery room after vecuronium. Br J Anaesth. 2000; 84: 394-395. CrossRef PubMed (Pubitemid 30114138)
3. Hayes AH, Mirakhur RK, Breslin DS, Reid JE, McCourt KC. Postoperative residual block after intermediate-acting neuromuscular blocking drugs. Anaesthesia. 2001; 56: 312-318. CrossRef PubMed (Pubitemid 32293887)
4. Kim KS, Lew SH, Cho HY, Cheong MA. Residual paralysis induced by either vecuronium or rocuronium after reversal with pyridostigmine. Anesth Analg. 2002; 95: 1656-1660. CrossRef PubMed (Pubitemid 35423956)
5. Murphy GS. Residual neuromuscular blockade: incidence, assessment, and relevance in the postoperative period. Minerva Anestesiol. 2006; 72: 97-109. PubMed
6. Maybauer DM, Geldner G, Blobner M, Pühringer F, Hofmockel R, Rex C, Wulf HF, Eberhart L, Arndt C, Eikermann M. Incidence and duration of residual paralysis at the end of surgery after multiple administrations of cisatracurium and rocuronium. Anaesthesia. 2007; 62: 12-17. Cross-Ref PubMed (Pubitemid 44869633)
7. Murphy GS, Brull SJ. Residual neuromuscular block: lessons unlearned. Part I: definitions, incidence, and adverse physiologic effects of residual neuromuscular block. Anesth Analg. 2010; 111: 120-128. PubMed
8. Adam JM, Bennett DJ, Bom A, Clark JK, Feilden H, Hutchinson EJ, Palin R, Prosser A, Rees DC, Rosair GM, Stevenson D, Tarver GJ, Zhang MQ. Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships. J Med Chem. 2002; 45: 1806-1816. Cross-Ref PubMed (Pubitemid 34415376)
9. Bom A, Bradley M, Cameron K, Clark JK, Van Egmond J, Feilden H, MacLean EJ, Muir AW, Palin R, Rees DC, Zhang MQ. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodex-trin- based synthetic host. Angew Chem Int Ed Engl. 2002; 41: 266-270. PubMed
10. Jones RK, Caldwell JE, Brull SJ, Soto RG. Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology. 2008; 109: 816-824. CrossRef PubMed
11. Blobner M, Eriksson LI, Scholz J, Motsch J, Della Rocca G, Prins ME. Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. Eur J Anaesthesiol. 2010; 27: 874-881. CrossRef PubMed
12. Khuenl-Brady KS, Wattwil M, Vanacker BF, Lora- Tamayo JI, Rietbergen H, Alvarez-Gómez JA. Sugammadex provides faster reversal of vecuroni-um- induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesth Analg. 2010; 110: 64-73. CrossRef PubMed
13. Lemmens HJ, El-Orbany MI, Berry J, Morte JB Jr, Martin G. Reversal of profound vecuronium-induced neuromuscular block under sevoflurane anesthesia: sugammadex versus neostigmine. BMC Anesthesiol. 2010; 10: 15.CrossRef PubMed
14. Stair C, Fernandez-Bustamante A. Sugammadex, the first selective relaxant binding agent for neuromuscular block reversal. Drugs Today (Barc). 2012; 48: 405-413. PubMed
15. European Medicines Agency. Summary of product characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/ human/000885/WC500052310.pdf (accessed April 15, 2013).
16. de Zwart MA, ten Bruggencate-Broeders J, van Hal HJ, Megens RH, Frasa HW. Determination of sugammadex in human plasma, urine, and dialysate using a high-performance liquid chromatography/ tandem mass spectrometry assay. J Chromatogr B Analyt Technol Biomed Life Sci. 2011; 879: 1573-1586. CrossRef PubMed
17. Kleine Budde I, de Heer PG, van der Zee JS, Aalberse RC. The stripped basophil histamine release bioassay as a tool for the detection of allergenspecific IgE in serum. Int Arch Allergy Immunol. 2001; 126: 277-285. CrossRef PubMed (Pubitemid 34124193)
18. Kitchen S, Cartwright I, Woods TA, Jennings I, Preston FE. Lipid composition of seven APTT reagents in relation to heparin sensitivity. Br J Haematol. 1999; 106: 801-808. CrossRef PubMed (Pubitemid 29434225)
19. Carlsson SC, Mattsson C, Eriksson UG, Sarich TC, Wåhlander K, Eliasson A, Karlson BW, Sheth SB, Held P. A review of the effects of the oral direct thrombin inhibitor ximelagatran on coagulation assays. Thromb Res. 2005; 115: 9-18. Cross-Ref PubMed (Pubitemid 39572749)
20. de Kam P-J, el Galta R, Kruithof AC, Fennema H, van Lierop M-J, Mihara K, Burggraaf J, Moerland M, Peeters P, Troyer MD. No clinically relevant interaction between sugammadex and aspirin on platelet aggregation and coagulation parameters. Int J Clin Pharmacol Ther. in press. PubMed
21. Kleijn HJ, Zollinger DP, van den Heuvel MW, Kerbusch T. Population pharmacokinetic-pharmacodynamic analysis for sugammadex-mediated reversal of rocuronium-induced neuromuscular blockade. Br J Clin Pharmacol. 2011; 72: 415-433. CrossRef PubMed
22. Peeters P, Passier P, Smeets J, Zwiers A, de Zwart M, van de Wetering-Krebbers S, van Iersel M, van Marle S, van den Dobbelsteen D . Sugammadex is cleared rapidly and primarily unchanged via renal excretion. Biopharm Drug Dispos. 2011; 32 : 159-167. CrossRef PubMed
23. Blann AD, Khoo CW. The prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants. Vasc Health Risk Manag. 2009; 5: 693-704. CrossRef PubMed
24. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ, Vandenbroucke JP, Briët E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med. 1995; 333: 11-17. CrossRef PubMed
25. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996; 335: 540-546. CrossRef PubMed (Pubitemid 26272308)
26. Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O'Gara PT, O'Rourke RA, Otto CM, Shah PM, Shanewise JS; 2006 Writing Committee Members; American College of Cardiology/ American Heart Association Task Force. Focused update incorporated into the ACC/ AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2008; 118: e523-e661. PubMed
27. Peeters PA, van den Heuvel MW, van Heumen E, Passier PC, Smeets JM, van Iersel T, Zwiers A. Safety, tolerability and pharmacokinetics of sugammadex using single high doses (up to 96 mg/kg) in healthy adult subjects: a randomized, double-blind, crossover, placebo-controlled, single-centre study. Clin Drug Investig. 2010; 30: 867-874. CrossRef PubMed
28. Menéndez-Ozcoidi L, Ortiz-Gómez JR, Olaguibel-Ribero JM, Salvador-Bravo MJ. Allergy to low dose sugammadex. Anaesthesia. 2011; 66: 217-219. CrossRef PubMed